Clinical trials: Endocrine Disorder
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00044694
- Testing
- AC2993 2.5 mcg
- Where
- 33 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin aspart produced by current process compared to that of insulin aspart produced by NN2000 process in subjects with type…
- Trial name
- NCT00604656
- Testing
- insulin aspart
- Where
- 34 sites in Czechia, Germany and 3 more
- Volunteers
- 241 people
- Sponsor
- Novo Nordisk A/S
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Reparixin in Pancreatic Islet Transplantation
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8.
- Trial name
- NCT01220856
- Testing
- Reparixin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 9 people
- Sponsor
- Dompé Farmaceutici S.p.A
Growth Hormone Deficiency
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
- Trial name
- NCT02410356
- Testing
- TV-1106, dGH
- Where
- 50 sites in United States, Austria and 6 more
- Volunteers
- 34 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Ovarian Cancer
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy.
- Trial name
- NCT04669002
- Testing
- EP0057, Olaparib tablets
- Where
- 21 sites in United States, Hungary and 1 more
- Volunteers
- 34 people
- Sponsor
- Ellipses Pharma
Pancreatic Cancer
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.
- Trial name
- NCT00810953
- Testing
- Pentamidine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Oncozyme Pharma Inc.
Type 2 Diabetes
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after…
- Trial name
- NCT05966272
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Thyroid Cancer
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
This is a patient pilot study testing the hypothesis that vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR) thyroid cancer patients.
- Trial name
- NCT02456701
- Testing
- KTN3379, vemurafenib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Celldex Therapeutics
Diabetes Mellitus, Type 2
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Primary objective: The primary objective of this trial is: To evaluate the efficacy of initiating Lantus in combination with oral antidiabetics drugs compared to oral antidiabetic treatment optimised by enhancing hygienic and…
- Trial name
- NCT00174681
- Testing
- Insulin Glargine
- Where
- 6 sites in Croatia, Czechia and 4 more
- Volunteers
- 390 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.
This is a research study of a study drug known as LY041001 or human insulin inhalation powder (HIIP). HIIP is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device.
- Trial name
- NCT00063128
- Testing
- insulin, human insulin inhalation powder (HIIP)
- Where
- 25 sites in United States
- Volunteers
- 119 people
- Sponsor
- Eli Lilly and Company
Ovarian Carcinoma
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal…
- Trial name
- NCT00853307
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
- Trial name
- GLOW2 (NCT06270836)
- Testing
- Tarcocimab
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Kodiak Sciences Inc
PreDiabetes
Avocado Snacks in a Prediabetic Population
Compare the effects of three evening snacks on morning fasting and postprandial glucose and insulin concentrations in individuals with prediabetes.
- Trial name
- AVOC4 (NCT05263011)
- Testing
- Avocado, low fat yogurt, low fat yogurt + fiber +fat
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Type 2 Diabetes Mellitus
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and…
- Trial name
- NCT02564211
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Adrenal Insufficiency
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
To describe clinical outcomes and both primary and secondary care health care resource use in patients who have been prescribed either immediate-release (IR) hydrocortisone or modified-release (MR) hydrocortisone or prednisolone…
- Trial name
- NCT03013166
- Testing
- Corticosteroid medication
- Volunteers
- 3,000 people
- Sponsor
- Shire
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Adult Growth Hormone Deficiency
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth…
- Trial name
- NCT01247675
- Testing
- ACP-001 (TransCon hGH), Omnitrope
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 37 people
- Sponsor
- Ascendis Pharma A/S
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Type II Diabetes Mellitus
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.
- Trial name
- NCT03084965
- Where
- 8 sites in Taiwan
- Volunteers
- 1,987 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.